Tempus Wealth Planning LLC Acquires 235 Shares of Bristol-Myers Squibb (NYSE:BMY)

Tempus Wealth Planning LLC boosted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.5% during the 3rd quarter, Holdings Channel reports. The firm owned 15,648 shares of the biopharmaceutical company’s stock after buying an additional 235 shares during the period. Tempus Wealth Planning LLC’s holdings in Bristol-Myers Squibb were worth $810,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Westhampton Capital LLC grew its holdings in Bristol-Myers Squibb by 75.4% during the 3rd quarter. Westhampton Capital LLC now owns 27,217 shares of the biopharmaceutical company’s stock valued at $1,408,000 after buying an additional 11,700 shares in the last quarter. Symphony Financial Ltd. Co. grew its holdings in shares of Bristol-Myers Squibb by 36.4% in the third quarter. Symphony Financial Ltd. Co. now owns 17,802 shares of the biopharmaceutical company’s stock valued at $930,000 after purchasing an additional 4,751 shares in the last quarter. Eastern Bank increased its position in Bristol-Myers Squibb by 715.3% in the third quarter. Eastern Bank now owns 45,290 shares of the biopharmaceutical company’s stock worth $2,343,000 after purchasing an additional 39,735 shares during the last quarter. Signaturefd LLC raised its stake in Bristol-Myers Squibb by 8.5% during the third quarter. Signaturefd LLC now owns 99,174 shares of the biopharmaceutical company’s stock valued at $5,131,000 after purchasing an additional 7,799 shares in the last quarter. Finally, Sequoia Financial Advisors LLC raised its stake in Bristol-Myers Squibb by 40.6% during the third quarter. Sequoia Financial Advisors LLC now owns 142,955 shares of the biopharmaceutical company’s stock valued at $7,397,000 after purchasing an additional 41,276 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Stock Performance

BMY opened at $52.76 on Wednesday. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $56.77. The company has a current ratio of 1.16, a quick ratio of 1.02 and a debt-to-equity ratio of 2.86. The firm has a market capitalization of $106.95 billion, a PE ratio of -17.02, a P/E/G ratio of 13.75 and a beta of 0.46. The firm has a 50 day moving average of $50.53 and a two-hundred day moving average of $46.35.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The business had revenue of $12.20 billion during the quarter, compared to analyst estimates of $11.54 billion. During the same quarter last year, the business posted $1.75 EPS. The company’s revenue was up 8.7% on a year-over-year basis. On average, analysts anticipate that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be paid a dividend of $0.60 per share. The ex-dividend date is Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.55%. Bristol-Myers Squibb’s payout ratio is -77.42%.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of research reports. TD Cowen boosted their target price on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Deutsche Bank Aktiengesellschaft reduced their price objective on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research note on Tuesday, July 23rd. Sanford C. Bernstein initiated coverage on Bristol-Myers Squibb in a research note on Thursday, October 17th. They issued a “market perform” rating and a $56.00 price objective for the company. Barclays lifted their target price on Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a report on Monday, October 7th. Finally, Jefferies Financial Group raised their price target on Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a research report on Wednesday, August 28th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $53.20.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.